Table 1 Baseline characteristics and outcomes of CMV and non-CMV groups

Age (years)

41.6 (3.4, 83.4)

45.1 (3.4, 83.4)

39.5 (15.6, 75.6)

0.116

37.6 (3.4, 75.6)

38 (3.4, 70.5)

36.6 (20.2, 75.6)

0.981

42 (13.5, 83.4)

46.1 (13.5, 83.4)

40.3 (15.6, 74.2)

0.070

Gender (Men)

76 (64.4%)

29 (69%)

47 (61.8%)

0.434

37 (75.5%)

8 (72.7%)

29 (76.3%)

1.000

39 (56.5%)

21 (67.7%)

18 (47.4%)

0.089

BMI

21.5 (13.6, 31.3)

20.3 (13.6, 29.8)

22.1 (14.1, 31.3)

0.182

21.5 (14.1, 31.3)

21.3 (16.6, 29.8)

21.5 (14.1, 31.3)

0.540

21.4 (13.6, 29.9)

20.2 (13.6, 26.3)

22.5 (14.5, 29.9)

0.166

Baseline IBD characteristics

 Disease duration (years)

4.0 (1.3, 22.5)

5.9 (1.3, 21.5)

3.5 (1.8, 22.5)

0.015*

3.7 (1.3, 22.5)

3.7 (1.3, 12.6)

3.6 (1.8, 22.5)

0.816

4.8 (1.3, 21.5)

7.6 (1.3, 21.5)

3.3 (2.0, 21.5)

0.005*

 Montreal classification

  B1

24 (49.0%)

4 (36.4%)

20 (52.6%)

0.342

  B2

21 (42.9%)

4 (36.4%)

17 (44.7%)

0.737

  B3

8 (16.3%)

3 (27.3%)

5 (13.2%)

0.355

  L1

16 (32.7%)

5 (45.5%)

11 (28.9%)

0.466

  L2

4 (8.2%)

1 (9.1%)

3 (7.9%)

1.000

  L3

26 (53.1%)

4 (36.4%)

22 (57.9%)

0.208

  L4

28 (57.1%)

8 (72.7%)

20 (52.6%)

0.311

CDAI

252.5 (46.9, 464.6)

268.5 (201, 379)

244.1 (46.9, 464.6)

0.442

Mayo score

10 (5, 12)

10 (7, 12)

10 (5, 12)

0.838

Severity: EMS or SES-CD

7 (3, 24)

9 (3, 22)

6 (3, 24)

0.152

3 (1, 3)

3 (1, 3)

3 (1, 3)

0.999

Colonic stricture

13 (31.0%)

6 (54.5%)

7 (22.6%)

IBD complications

47 (39.8%)

17 (40.5%)

30 (39.5%)

0.915

31 (63.3%)

10 (90.9%)

21 (55.3%)

0.038*

16 (23.2%)

7 (22.6%)

9 (23.7%)

0.914

The extent of CMV colitis

 Ascending

14 (33.3%)

3 (27.3%)

11 (35.5%)

 Transverse

17 (40.5%)

4 (36.4%)

13 (41.9%)

 Descending

27 (64.3%)

1 (9.1%)

26 (83.9%)

 Sigmoid

35 (83.3%)

4 (36.4%)

31 (100%)

 Rectum

33 (78.6%)

3 (27.3%)

30 (96.8%)

IBD Medication

 Biological failure

33 (28%)

10 (23.8%)

23 (30.3%)

0.455

18 (36.7%)

2 (18.2%)

16 (42.1%)

0.178

15 (21.7%)

8 (25.8%)

7 (18.4%)

0.459

 Biologics user

34 (28.8%)

11 (26.2%)

23 (30.3%)

0.847

15 (30.6%)

4 (36.4%)

11 (28.9%)

0.496

19 (27.5%)

7 (22.6%)

12 (31.6%)

0.367

 5-ASA (oral)

8 (6.8%)

4 (9.5%)

4 (5.3%)

0.453

3 (6.1%)

3 (27.3%)

0 (0%)

0.009

5 (7.2%)

1 (3.2%)

4 (10.5%)

0.370

 Oral prednisolone

64 (54.2%)

23 (54.8%)

41 (53.9%)

0.932

22 (44.9%)

6 (54.5%)

16 (42.1%)

0.510

42 (60.9%)

17 (54.8%)

25 (65.8%)

0.354

 Dosage (mg/day)

5 (0, 45)

7.5 (0, 24)

5 (0, 45)

0.962

0 (0, 45)

10 (0, 24)

0 (0, 45)

0.350

10 (0, 30)

5 (0, 20)

10 (0, 30)

0.314

 Azathiopurine

33 (28%)

10 (23.8%)

23 (30.3%)

0.455

17 (34.7%)

4 (36.4%)

13 (34.2%)

1.000

16 (23.2%)

6 (19.4%)

10 (26.3%)

0.496

 Antibiotics

41 (34.7%)

20 (47.6%)

21 (27.6%)

0.029*

16 (32.7%)

7 (63.6%)

9 (23.7%)

0.025*

25 (36.2%)

13 (41.9%)

12 (31.6%)

0.373

 Hydrocortisone enema

9 (7.6%)

6 (14.3%)

3 (3.9%)

0.067

2 (4.1%)

0 (0%)

2 (5.3%)

1.000

7 (10.1%)

6 (19.4%)

1 (2.6%)

0.040*

Clinical presentation

 Bloody stool

80 (67.8%)

32 (76.2%)

48 (63.2%)

0.147

24 (49%)

7 (63.6%)

17 (44.7%)

0.269

56 (81.2%)

25 (80.6%)

31 (81.6%)

0.921

 Diarrhoea

75 (63.6%)

29 (69.0%)

46 (60.5%)

0.357

25 (51%)

6 (54.5%)

19 (50%)

0.791

50 (72.5%)

23 (74.2%)

27 (71.1%)

0.771

 Pain

74 (62.7%)

26 (61.9%)

48 (63.2%)

0.893

34 (69.4%)

7 (63.6%)

27 (71.1%)

0.716

40 (58%)

19 (61.3%)

21 (55.3%)

0.614

 Fever

18 (15.3%)

8 (19.0%)

10 (13.2%)

0.394

8 (16.3%)

3 (27.3%)

5 (13.2%)

0.355

10 (14.5%)

5 (16.1%)

5 (13.2%)

0.745

Laboratory data

 WBC (1000/µL)

8 (2.1, 26.5)

7.5 (4.2, 20.4)

8.1 (2.1, 26.5)

0.766

7.3 (2.1, 26.5)

7 (5.2, 20.4)

7.9 (2.1, 26.5)

0.792

8.7 (4, 20)

8.7 (4.2, 13.3)

8.7 (4, 20)

0.466

 Haemoglobin (g/L)

119 (49, 159)

115 (74, 159)

121 (49, 156)

0.396

115 (72, 159)

112 (82, 159)

116 (72, 155)

0.590

121 (49, 156)

118 (74, 150)

125 (49, 156)

0.326

 CRP (g/L)

0.09 (0.002, 1.765)

0.07 (0.002, 1.121)

0.09 (0.002, 1.765)

0.779

0.100 (0.002, 1.378)

0.110 (0.003, 1.121)

0.100 (0.002, 1.378)

0.915

0.06 (0.002, 176.5)

0.06 (0.002, 0.97)

0.07 (0.007, 1.765)

0.989

 Albumin (g/L)

37 (14, 48)

30 (14, 4.4)

39 (2.2, 4.8)

0.008*

39 (22, 47)

42 (22, 44)

38 (25, 47)

0.842

36 (14, 48)

30 (14, 43)

40 (22, 48)

0.006*

 CMV-IgM

6 (6.8%)

4 (12.9%)

2 (3.5%)

0.179

2 (5.7%)

1 (12.5%)

1 (3.7%)

0.410

4 (7.5%)

3 (13%)

1 (3.3%)

0.305

 CMV-IgG

68 (81%)

28 (96.6%)

40 (72.7%)

0.008*

26 (76.5%)

7 (87.5%)

19 (73.1%)

0.645

42 (84%)

21 (100%)

21 (72.4%)

0.015*

 CMV viremia

5 (16.7%)

5 (45.5%)

0 (0%)

0.003^*

2 (15.4%)

2 (66.7%)

0 (0%)

0.038*

3 (17.6%)

3 (37.5%)

0 (0%)

0.082

 CMV antigenemia

2 (5.4%)

2 (15.4%)

0 (0%)

0.117

0 (0%)

0 (0%)

0 (0%)

-

2 (8.7%)

2 (20.0%)

0 (0%)

0.178

Anti-viral agents

 Intravenous ganciclovir

18 (43.9%)

18 (43.9%)

-

-

4 (40%)

4 (40%)

-

-

14 (45.2%)

14 (45.2%)

-

-

 Intravenous duration (days)

15 (7, 49)

15 (7, 49)

-

-

15 (7, 21)

15 (7, 21)

-

-

15 (8, 49)

15 (8, 49)

-

-

 Oral Valganciclovir

26 (63.4%)

26 (63.4%)

-

-

5 (50%)

5 (50%)

-

-

21 (67.7%)

21 (67.7%)

-

-

 Oral duration (days)

16 (6, 129)

16 (6, 129)

-

-

14 (7, 49)

14 (7, 49)

-

-

16 (6, 129)

16 (6, 129)

-

-

 Total duration (days)

22 (7, 129)

22 (7, 129)

-

-

21 (7, 64)

21 (7, 64)

-

-

23.5 (7, 129)

23.5 (7, 129)

-

-

Outcomes

 Recurrence

6 (23.1%)

6 (23.1%)

-

-

2 (33.3%)

2 (33.3%)

-

-

4 (20%)

4 (20.0%)

-

-

 Recurrence time (months)

25.4 (1.8, 198)

25.4 (1.8, 198)

-

-

68.9 (1.8, 136)

68.9 (1.8, 136)

-

-

25.4 (7.4, 198)

25.4 (7.4, 198)

-

-

 Clinical remission

81 (68.6%)

27 (64.3%)

54 (71.1%)

0.448

36 (73.5%)

8 (72.7%)

28 (73.7%)

1.000

45 (65.2%)

19 (61.3%)

26 (68.4%)

0.536

 Steroid free clinical remission

65 (55.1%)

22 (52.4%)

43 (56.6%)

0.661

28 (57.1%)

6 (54.5%)

22 (57.9%)

1.000

37 (53.6%)

16 (51.6%)

21 (55.3%)

0.762

 Hospitalization times

2 (0, 27)

2 (0, 27)

2 (0, 12)

0.180

3 (0, 27)

2 (0, 27)

3 (0, 12)

0.561

2 (0, 12)

2 (0, 9)

2 (0, 12)

0.434

 Steroid dose change

-4.5 (-44, 1)

-7 (-24, 1)

-4 (-44, 1)

0.938

0 (-44, 1)

-9 (-24, 1)

0 (-44, 1)

0.358

-9 (-30, 1)

-5 (-20, 1)

-9 (-30, 1)

0.223

 CDAI change

-116.3 (-396.6, 88)

-155 (-322, 54)

-115.9 (-396.6, 88)

0.896

-115.4 (-396.6, 88)

-162.8 (-322, -68)

-112.6 (-396.6, 88)

0.533

-122.6 (-183, 54)

54 (54, 54)

-124.4 (-183, -120.7)

0.500

 Mayo score change

-6 (-12, 1)

-5 (-12, 1)

-6 (-11, 0)

0.929

-

-

-

-

-6 (-12, 1)

-5 (-12, 1)

-6 (-11, 0)

0.929

 BMI change

0.8 (-5.5, 13.3)

0.6 (-3.6, 5.3)

1 (-5.5, 13.3)

0.584

0.8 (-3.3, 13.3)

1.4 (-0.9, 3.8)

0.8 (-3.3, 13.3)

0.828

0.9 (-5.5, 7.5)

0.1 (-3.6, 5.3)

1.1 (-5.5, 7.5)

0.447

 IBD complications

53 (44.9%)

20 (47.6%)

33 (43.4%)

0.661

31 (63.3%)

7 (63.6%)

24 (63.2%)

1.000

22 (31.9%)

13 (41.9%)

9 (23.7%)

0.106

 Stricture

38 (32.2%)

12 (28.6%)

26 (34.2%)

0.530

25 (51.0%)

5 (45.5%)

20 (52.6)

0.675

13 (18.8%)

7 (22.6%)

6 (15.8%)

0.473

 Perforation

6 (5.1%)

3 (7.1%)

3 (3.9%)

0.665

4 (8.2%)

2 (18.2%)

2 (5.3%)

0.214

2 (2.9%)

1 (3.2%)

1 (2.6%)

1.000

 Abscess

9 (7.6%)

5 (11.9%)

4 (5.3%)

0.277

5 (10.2%)

2 (18.2%)

3 (7.9%)

0.311

4 (5.8%)

3 (9.7%)

1 (2.6%)

0.319

 Fistula

13 (11.0%)

3 (7.1%)

10 (13.2%)

0.375

11 (22.4%)

1 (9.1%)

10 (26.3%)

0.415

2 (2.9%)

2 (6.5%)

0 (0%)

0.198

 Colon cancer

4 (3.4%)

3 (7.1%)

1 (1.3%)

0.128

1 (2%)

1 (9.1%)

0 (0%)

0.224

3 (4.3%)

2 (6.5%)

1 (2.6%)

0.584

 IBD surgery

36 (30.5%)

16 (38.1%)

20 (26.3%)

0.183

19 (38.8%)

5 (45.5%)

14 (36.8%)

0.729

17 (24.6%)

11 (35.5%)

6 (15.8%)

0.059

 Death

5 (4.6%)

2 (5.9%)

3 (4.0%)

0.646

2 (4.1%)

0 (0%)

2 (5.3%)

1.000

3 (5%)

2 (8.7%)

1 (2.7%)

0.552

Follow-up duration (months)

21.1 (0, 192.1)

21.3 (0.4, 192.1)

21.1 (0, 57.6)

0.467

22.8 (0.3, 63.3)

26.3 (10.4, 63.3)

21.8 (0.3, 57.6)

0.465

19.1 (0, 192.1)

19.1 (0.4, 192.1)

18.5 (0, 56.1)

0.546